186 Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1

• Karrie Wong,
• Sharon Lin,
• Christopher Wrocklage,
• Katri Sofjan,
• Leila Williams,
• Mallory Brady,
• Nicholas Colletti,
• Noah Tubo,
• Hugh Gannon,
• Robert LaMothe,
• Tianlei Xu,
• Tracy VandenBerg,
• Sol Shenker,
• Caroline Dugopolski,
• Frank Stegmeier,
• Louise Cadzow,
• Michael Schlabach,
• Micah Benson

Affiliations

Karrie Wong

KSQ Therapeutics, Cambridge, MA, USA

Sharon Lin

KSQ Therapeutics, Cambridge, MA, USA

Christopher Wrocklage

KSQ Therapeutics, Cambridge, MA, USA

Katri Sofjan

KSQ Therapeutics, Cambridge, MA, USA

Leila Williams

KSQ Therapeutics, Cambridge, MA, USA

Mallory Brady

KSQ Therapeutics, Cambridge, MA, USA

Nicholas Colletti

KSQ Therapeutics, Cambridge, MA, USA

Noah Tubo

KSQ Therapeutics, Cambridge, MA, USA

Hugh Gannon

KSQ Therapeutics, Cambridge, MA, USA

Robert LaMothe

KSQ Therapeutics, Cambridge, MA, USA

Tianlei Xu

KSQ Therapeutics, Cambridge, MA, USA

Tracy VandenBerg

KSQ Therapeutics, Cambridge, MA, USA

Sol Shenker

KSQ Therapeutics, Cambridge, MA, USA

Caroline Dugopolski

KSQ Therapeutics, Cambridge, MA, USA

Frank Stegmeier

KSQ Therapeutics, Cambridge, MA, USA

Louise Cadzow

KSQ Therapeutics, Cambridge, MA, USA

Michael Schlabach

KSQ Therapeutics, Cambridge, MA, USA

Micah Benson

KSQ Therapeutics, Cambridge, MA, USA